Mark Cuban Lists 6 Big Fixes That Could Save 'Hundreds of Billions' Under Trump's New Healthcare Order — 'Put Me In, Coach!'

Mark Cuban isn't sitting on the sidelines when it comes to healthcare reform — and he's got six plays ready to run. After President Donald Trump announced a new executive order targeting healthcare costs, Cuban jumped in with rare praise, calling it a potential game-changer for drug pricing.

"Gotta be honest," Cuban posted on X. "The @realDonaldTrump EO on healthcare and in particular, drug pricing could save hundreds of billions."

Don't Miss:

• Deloitte's fastest-growing software company partners with Amazon, Walmart & Target – Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!
• Are you rich? Here’s what Americans think you need to be considered wealthy.

And he wasn't just tossing compliments. He laid out exactly how it could happen — starting with a hard reset on how prescription drugs are priced, sold, and managed.

Here's the gist of Cuban's six-part game plan:

Today's Best Finance Deals

Take Formularies Away From PBMs

First, Cuban said it's time to "divorce formularies from PBMs." In plain English, that means pharmacy benefit managers — the middlemen between drugmakers and insurance plans — shouldn't be the ones deciding what drugs get covered. Instead, independent groups with no financial ties should be in charge.

"They should be about wellness, not pay-for-play like a grocery store endcap," Cuban said. No more rebates, no more shady deals — just pricing that actually reflects patient care.

Give Claims Data to the People Who Need It

Right now, PBMs guard insurance claims data like it's the crown jewels. Cuban called that "insane." He wants PBMs to be forced to hand over all claims data to employers, states, and drugmakers — the ones who can actually use it to improve treatments.

Trending: It’s no wonder Jeff Bezos holds over $250 million in art — this alternative asset has outpaced the S&P 500 since 1995, delivering an average annual return of 11.4%. Here’s how everyday investors are getting started.

Manufacturers already pay 5% to 10% of a drug's retail price just to buy data they should've gotten for free, Cuban pointed out. Ending that would mean savings baked right into lower prices.

Kill the ‘Specialty Tier' and Pharmacy Restrictions

Cuban didn't pull punches here: "There is nothing special about specialty drugs." He said drug companies slap the "specialty" label on medications just to jack up prices. His fix? Get rid of the specialty tier system and let patients buy from any pharmacy — not just the one PBMs pick to pad their profits.

Protect Independent Pharmacies

Pharmacies that aren't tied to giant corporations are getting crushed, and Cuban says the system is rigged against them. He wants brand-name drug reimbursements fully restored and the "Generic Cost Ratio" junked — a sneaky loophole that lets distributors hike prices on generic meds.

End Confidentiality Clauses

Believe it or not, Cuban says companies can't even talk directly to drugmakers about better deals or wellness programs because of confidentiality clauses. "It's insane that your company can't talk to a GLP1 manufacturer (as an example) to help you put together a wellness plan and get you a better price," he said. He wants that nonsense scrapped.

See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — invest pre-IPO from $0.60 per share now.

Stop Shady Biosimilar Substitution Calls

Last but not least, Cuban blasted PBMs for playing dirty with biosimilar drugs — cheaper alternatives to expensive biologics. They're supposed to offer lower-cost options, but Cuban says PBMs push their own higher-margin versions instead. They even call doctors to swap prescriptions behind the scenes.

"And because employers and manufacturers don't get their data," Cuban said, "they never know."

At the end of his post, Cuban added: "Put me in coach! I'm here to help."

Mark Cuban isn't just tossing out ideas — he's practically pacing the sidelines, ready to check in. Whether anyone hands him a clipboard remains to be seen, but there's still time on the clock and Cuban's ready to run a full-court press on a system that's been coasting for too long.

Cuban's Cost Plus Drugs model — which cuts out middlemen and sells medications directly to consumers — could gain serious credibility if broader reforms start to reshape the industry. While his company is already pushing for more transparency and lower drug prices, Cuban's bigger healthcare ambitions are clear: he's not just trying to build a better pharmacy, he's pushing for a system that actually works for patients — with or without a government playbook.

Read Next:

• Can you guess how many Americans successfully retire with $1,000,000 saved? The percentage may shock you.
• ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can invest today for just $0.26/share with a $1000 minimum.

Image: Shutterstock